Abstract Number: 2259 • 2014 ACR/ARHP Annual Meeting
Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
Background/Purpose ,Osteoporosis is one of the serious complications of systemic glucocorticoid therapy. Reduced bone formation is the key process in patients with glucocorticoid-induced osteoporosis (GIOP),…Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…Abstract Number: 2732 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Autophagy Prevents Ovariectomy Induced Bone Loss
Background/Purpose: Autophagy is an essential, homeostatic process by which cells digest unnecessary or damaged organelles. Atg7 is essentially required for formation of the autophagosome. The…Abstract Number: 2664 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Osteoporosis Medication Starts In Patients Based On T-Score and FRAX® Absolute Fracture Risk Model In a Large Health Care System
Background/Purpose: The National Osteoporosis Foundation (NOF) 2008 guidelines recommend treatment for postmenopausal women (PMW) and men ≥ 50 if the T-score is ≤-2.5 at the…Abstract Number: 2266 • 2013 ACR/ARHP Annual Meeting
Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption and formation are respectively increased and inhibited in patients with…Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…Abstract Number: 1924 • 2013 ACR/ARHP Annual Meeting
Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data
Background/Purpose: A patient registry is an organized system that collects uniform data to allow evaluation of specific outcomes for a population with a particular disease.…Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…Abstract Number: 1243 • 2013 ACR/ARHP Annual Meeting
Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting
Background/Purpose: Medication adherence with prescription osteoporosis medications is poor, with approximately half remaining adherent in the first year of treatment. Moreover, approximately one-third who are…Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting
Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…Abstract Number: 982 • 2013 ACR/ARHP Annual Meeting
Preferred Strategies For Delivering Treatment Information To People With Rheumatoid Arthritis, Osteoarthritis and Osteoporosis
Background/Purpose: To explore the perceptions of people with rheumatoid arthritis (RA), osteoarthritis (OA), and osteoporosis (OP) regarding their preferred delivery methods for obtaining treatment information…Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…